Skip to main content
    F

    FibroBiologics, Inc. Common Stock (FBLG)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.90
    -0.02 (-2.56%)

    Market Cap: $6.57M

    Last updated: Nov 17, 2026 at 11:01 AM ET

    FibroBiologics, Inc. Common Stock (FBLG) Financials: Revenue, Profit and Cash Flow

    Updated Jul 31, 2026. Financial statements from company filings, amounts in US dollars.

    FibroBiologics, Inc. Common Stock reported revenue of $0 for the fiscal year ended Jun 30, 2026. That year, net income was -$18.65M, operating cash flow was -$16.39M and free cash flow was -$16.66M. The quarter ended Jun 30, 2026 had revenue of $0 and net income of -$4.12M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Jun 2026, with an operating loss of $16.65M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Jun 2026$0N/AN/AN/AN/A
    Jun 2025$0N/AN/AN/AN/A
    Jun 2024$0N/AN/AN/AN/A
    Jun 2023$0N/AN/AN/AN/A
    Jun 2022$0N/AN/AN/AN/A
    Jun 2021N/AN/AN/AN/AN/A
    Annual, fiscal years ended Jun 2021 to Jun 2026

    Income Statement

    In the fiscal year ended Jun 2026, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemJun 2026Jun 2025Jun 2024Jun 2023Jun 2022Jun 2021
    Cost of revenue$832.00K$573.00K$437.00K$94.00KN/AN/A
    Gross profit-$832.00K-$573.00K-$437.00K-$94.00KN/AN/A
    Research and development$7.41M$4.50M$2.37M$1.15M$521.00K$669.00K
    Operating income-$16.65M-$13.74M-$8.89M-$4.47M-$1.58M-$1.17M
    Net income-$18.65M-$11.16M-$16.48M-$5.12M-$1.58M-$1.17M
    EBITDAN/A-$10.57MN/A-$4.37M-$1.58MN/A
    Fiscal years ended Jun 2021 to Jun 2026

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$0$0$0$0$0$0$554.00K$0$0$0$0$0
    Gross profitN/AN/A-$234.00K-$231.00K-$206.00KN/A$277.00KN/A-$140.00K-$137.00K-$130.00K-$112.00K
    Operating income-$4.03M-$5.07M-$2.59M-$5.04M-$4.49M-$4.53M-$3.71M-$3.35M-$3.22M-$3.45M-$2.48M-$2.05M
    Net income-$4.12M-$5.00M-$3.24M-$5.78M-$4.66M-$4.97M-$3.10M-$500.00K$898.00K-$8.46M-$9.72M-$2.19M
    Last 12 quarters

    Balance Sheet

    As of Jun 2026, cash and equivalents exceeded short-term debt of $706.00K by $4.19M.

    Annual

    Line itemJun 2026Jun 2025Jun 2024Jun 2023Jun 2022Jun 2021
    Total assets$9.62M$16.45M$11.82M$4.82M$468.00KN/A
    Current assets$6.35M$14.23M$9.21M$2.63M$468.00KN/A
    Cash and equivalents$4.89M$13.98M$9.16M$2.27M$407.00KN/A
    Total liabilities$3.46M$13.71M$10.57M$8.82M$1.76MN/A
    Short-term debt$706.00K$9.57M$362.00K$5.78M$1.30MN/A
    Shareholder equity$6.16M$2.73M$1.25M-$4.00M-$1.29MN/A
    Fiscal years ended Jun 2021 to Jun 2026

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$7.93M$5.94M$9.62M$8.74M$13.91M$11.43M$16.45M$10.47M$8.91M$11.40M$11.82M$13.30M
    Total liabilities$3.29M$3.34M$3.46M$8.62M$13.05M$9.08M$13.71M$7.73M$11.30M$15.26M$10.57M$2.76M
    Cash and equivalents$3.52M$1.48M$4.89M$4.87M$8.85M$8.67M$13.98M$7.83M$5.97M$8.16M$9.16M$10.77M
    Shareholder equity$4.64M$2.60M$6.16M$125.00K$860.00K$2.35M$2.73M$2.74M-$2.39M-$3.86M$1.25M$10.54M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Jun 2026.

    Annual

    Line itemJun 2026Jun 2025Jun 2024Jun 2023Jun 2022Jun 2021
    Operating cash flow-$16.39M-$11.90M-$6.40M-$4.07M-$1.41M-$1.17M
    Capital expenditures$262.00K$184.00K$495.00K$0$0$0
    Free cash flow-$16.66M-$12.09M-$6.90M-$4.07M-$1.41M-$1.17M
    Investing cash flow-$262.00K-$184.00K-$495.00KN/AN/AN/A
    Financing cash flow$7.57M$16.91M$13.79M$5.92M$1.82M$1.17M
    Fiscal years ended Jun 2021 to Jun 2026

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$3.29M-$4.36M-$3.16M-$3.97M-$3.98M-$5.28M-$3.07M-$2.61M-$1.95M-$4.28M-$1.60M-$1.14M
    Capital expenditures$0$0$0$6.00K$213.00K$43.00K$99.00K$11.00K$66.00K$8.00K$2.00K$413.00K
    Free cash flow-$3.29M-$4.36M-$3.16M-$3.98M-$4.20M-$5.32M-$3.17M-$2.62M-$2.01M-$4.28M-$1.60M-$1.55M
    Last 12 quarters

    Frequently Asked Questions About FBLG

    What is FibroBiologics, Inc. Common Stock's annual revenue?

    FibroBiologics, Inc. Common Stock reported revenue of $0 for the fiscal year ended Jun 30, 2026.

    Is FibroBiologics, Inc. Common Stock profitable?

    No. FibroBiologics, Inc. Common Stock reported net income of -$18.65M for the fiscal year ended Jun 30, 2026.

    How much free cash flow does FBLG generate?

    For the fiscal year ended Jun 30, 2026, operating cash flow of -$16.39M minus capital expenditures of $262.00K produced free cash flow of -$16.66M.

    How much debt does FibroBiologics, Inc. Common Stock have?

    The balance sheet dated Jun 30, 2026 reported short-term debt of $706.00K and cash and equivalents of $4.89M.